"The University of Edinburgh wishes to acknowledge the validity of Pelago’s CETSA patent (EP 2 699 910 B1) entitled "Methods For Determining Ligand Binding To A Target Protein Using A Thermal Shift Assay" (the "Patent") and the use of the Cellular Thermal Shift Assay (CETSA®) process described in the Patent in relation to the following works: Carolin Temps et al., "A novel mode of inhibiting SRC improves drug efficacy and tolerability", Cancer Research, 20 August 2021, DOI: 10.1158/0008-5472.CAN-21 0613; Chiara Asselborn, Kevin Myant and Alex von Kriegsheim, "Selective vulnerability of colorectal cancer (CRC) organoids to hypoxia-mimetic drug", presented at the National Cancer Research Institute Cancer Conference in 2018; and; PhD student research to validate binding between integrin linked kinase and three compounds proposed to bind the protein undertaken in around February 2021"